Stem Cell Clinic

Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs – ResearchAndMarkets.com…

DUBLIN--(BUSINESS WIRE)--The "Heart Failure - Pipeline Insight" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Heart Failure - Pipeline Insight, 2022" report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Heart Failure - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines.

The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Heart Failure Emerging Drugs

Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for chronic weight management and heart failure with preserved ejection fraction (HFpEF). It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH). Both the FDA and EMA have accepted Eli Lilly's marketing approval applications for its type 2 diabetes treatment, tirzepatide.

Finerenone (BAY94-8862): Bayer

Finerenone (BAY 94-8862) is an investigational novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block the harmful effects of the overactivated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. Current steroidal MRAs on the market have proven to be effective in reducing cardiovascular mortality in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, they are often underutilized due to the incidence of hyperkalemia, renal dysfunction, and anti-androgenic/ progestogenic side effects.

CardiAMP Cell Therapy: BioCardia

CardiAMP Cell Therapy uses a patient's own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body's natural healing response. The CardiAMP Cell Therapy Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively screen for cell therapeutic potency in order to improve patient outcomes. CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in investigational cardiac cell therapy, which the company believes improves the probability of success of the treatment: a pre-procedural diagnostic for patient selection, a high target dosage of cells, and a proprietary delivery system that has been shown to be safer than other intramyocardial delivery systems and more successful for enhancing cell retention.

Rexlemestrocel-L (Revascor): Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors.

BMS-986231: Bristol-Myers Squibb

Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. HNO gas (nitroxyl) is a chemical sibling of nitric oxide. Although nitric oxide and HNO appear to be closely related chemically, the physiological effects and biologic mechanisms of HNO and nitric oxide action are distinct. The biologic effects of HNO are mediated by direct post-translational modification of thiol residues in target proteins, including SERCA2a, phospholamban, the ryanodine receptor, and myofilament proteins in cardiomyocytes. In vitro, HNO increases the efficiency of calcium cycling and improves myofilament calcium sensitivity, which enhances myocardial contraction and relaxation. HNO also mediates peripheral vasodilation through endothelial soluble guanylate cyclase. HNO does not induce tachyphylaxis in peripheral vessels, unlike nitric oxide.

Elamipretide: Stealth BioTherapeutics

Elamipretide (MTP-131, Bendavia) is a novel tetra-peptide that targets mitochondrial dysfunction in energydepleted myocytes. Elamipretide crosses the outer membrane of the mitochondria and associates itself with cardiolipin, which is a phospholipid expressed only in the inner membrane of mitochondria. Cardiolipin has an integral role in mitochondrial stability and organization of respiratory complexes into super complexes for oxidative phosphorylation.Thus, elamipretide helps to enhance ATP synthesis in multiple organs of the body. Elamipretide has been shown to improve left ventricular ejection fraction (LVEF), LV end diastolic pressure, cardiac hypertrophy, myocardial fibrosis, and myocardial ATP synthesis in both animal models and humans.

FA relaxin: Bristol Myers Squibb

BMS-986259 is a next-generation version of Relaxin that is enabled with our technology and currently in Phase 1 clinical trials for ADHF. Relaxin, a peptide hormone, has been reported to reduce fibrosis in the multiple organs and to exert cardioprotective effects in preclinical studies. However, the therapeutic potential of Relaxin has been partially limited by its short half-life in humans. BMS-986259 has exhibited a prolonged half-life and therefore has the potential to enhance clinical benefit as a novel therapeutic for ADHF.

Key Players

Key Products

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/soc45u

Read more:
Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs - ResearchAndMarkets.com...

Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety…

Abstract: C-type lectin like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia (AML) stem cells and AML blasts, and can be considered as AML-associated antigen. Anti-CLL1-based CAR-T cells exhibited effective tumor killing capacity in vitro and in AML-bearing mouse model. In this report, eight children with relapsed or refractory AML (R/R-AML) were recruited for a phase 1/2 clinical trial of autologous anti-CLL1 CAR-T cell immunotherapy. The objectives of this clinical trial were to evaluate the safety and the anti-AML responses after CLL1-CAR-T cell treatment, with long-term prognosis within those patients who did not receive allogeneic hematopoietic stem cells transplantation (allo-HSCT) as an additional aim. These R/R-AML patients received one dose of autologous CLL1-CAR-T cells after lymphodepletion conditioning. Grade 34 hematologic adverse events were observed post CAR-T cell infusion. Meanwhile, grade 12 cytokine release syndrome (CRS) was observed but without any lethal events. 4 out of 8 AML patients achieved incomplete remission (CRi) and minimal residual disease (MRD) negativity, 2 patients with CRi but MRD positivity, and 2 patients with decreased AML burden and CLL1 positive AML blast clearance. These results suggested that anti-CLL1-based CAR-T cell immunotherapy can be considered as a well-tolerated and effective option for treating children with R/R-AML.

See the article here:
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety...

Stem Cell Therapy Market 2022 Growing with Major Eminent Key Players Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and Pharmicell…

The global Fluoropolymer Films Market study intends to deliver a thorough understanding of the market situation in the present, past along with future projections and market estimations framed based on evidential data provided by marketers. This set of data includes the market size and volume of the Global Fluoropolymer Films Market with respect to current market dynamics and the anticipated business size during the forecast graphically represented. Essential data regarding the cost-structure, supply chain and revenue is portrayed as a whole and with granular classification categorizing the Global Fluoropolymer Films Market into business level, industrial level and regional level defining the business growth of the Global Fluoropolymer Films Market in future.

Additionally, the supplies ideal little company options to the market. The Fluoropolymer Films report highlights the contemporary trends, improvements, demanding little business opportunities, along with other essential information of the net wide Fluoropolymer Films marketplace. Requirement ratio as well as the development of innovative technologies are a few the essential elements thats frequently discussed in the net Fluoropolymer Films marketplace listing.

Free Sample Report + All Related Graphs & Charts @ https://www.adroitmarketresearch.com/contacts/request-sample/1524?utm_source=PT

Leading players of Fluoropolymer Films Market including:

The Chemours Company, 3M, Saint-Gobain, Nitto Denko, Honeywell International, Daikin, Rogers Corporation, DUNMORE, AGC Chemicals, Guarniflon, Textiles Coated International

Fluoropolymer Films Market Analysis is a top-notch professionally designed and employed synopsis of this international industry that encloses substantial details on drivers and restraints analytics, inclusive of different market opportunities and challenges which are most likely to influence general growth situation pertaining to international Fluoropolymer Films marketplace. The report hooks significant developments on regional growth prospects, but before exactly the very same, the report incorporates flexible information on Fluoropolymer Films market segmentation that uniquely identifies application and type as important growth segments and components.

Thorough evaluation of the important players who function from the Fluoropolymer Films market area together with their placement in addition to contribution to the market, their investment portfolio in addition to some other insights is emphasized in the study record. Whats more, the report includes recent upgrades, Fluoropolymer Films market asks and critical business methods that that assist the business together with the companies operating inside. Likewise, the record provides thorough analysis of their new mergers, investors, stakeholders and acquisitions who will have enormous effect on the Fluoropolymer Films industry space in the next several years.

The Fluoropolymer Films analysis is used in the timeline forecast to estimate the accurate market share. Market revenue forecasts are provided for each geographic region in the Fluoropolymer Films research report. An overview of the industrys growth opportunities, emerging innovations focused on creative business models, a range of value-added goods, and the competitive context of the competition that can fuel market growth are also included in the report. Similarly, the report provides the most up-to-date forecasts of global demand for the next five years.

Fluoropolymer Films market Segmentation by Type:

Polytetrafluoroethylene (PTFE) films Polyvinylidene fluoride (PVDF) films Fluorinated Ethylene Propylene (FEP) films Perfluoroalkoxy Polymer (PFA) films Ethylene Tetrafluoroethylene (ETFE) films Others

Fluoropolymer Films market Segmentation by Application:

Electrical & Electronics Industrial Automotive & Aerospace Medical & Pharmaceutical Consumer Products Others

Predominant Questions Answered in This Report Are:

1. Which segments will perform well in the Fluoropolymer Films market over the forecasted years? 2. In which markets companies should authorize their presence? 3. What are the forecasted growth rates for the market? 4. What are the long-lasting defects of the industry? 5. How share market changes their values by different manufacturing brands? 6. What are the qualities and shortcomings of the key players? 7. What are the major end results and effects of the five strengths study of industry?

Table of Content:

1 Scope of the Report 1.1 Market Introduction 1.2 Research Objectives 1.3 Years Considered 1.4 Market Research Methodology 1.5 Economic Indicators 1.6 Currency Considered 2 Executive Summary 3 Global Fluoropolymer Films by Players 4 Fluoropolymer Films by Regions 4.1 Fluoropolymer Films Market Size by Regions 4.2 Americas Fluoropolymer Films Market Size Growth 4.3 APAC Fluoropolymer Films Market Size Growth 4.4 Europe Fluoropolymer Films Market Size Growth 4.5 Middle East & Africa Fluoropolymer Films Market Size Growth 5 Americas 6 APAC 7 Europe 8 Middle East & Africa 9 Market Drivers, Challenges and Trends 9.1 Market Drivers and Impact 9.1.1 Growing Demand from Key Regions 9.1.2 Growing Demand from Key Applications and Potential Industries 9.2 Market Challenges and Impact 9.3 Market Trends 10 Global Fluoropolymer Films Market Forecast 11 Key Players Analysis 12 Research Findings and Conclusion

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1524?utm_source=PT

ABOUT US:

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

CONTACT US:

Ryan Johnson Account Manager Global 3131 McKinney Ave Ste 600, Dallas, TX 75204, U.S.A Phone No.: USA: +1.210.667.2421/ +91 9665341414

More:
Stem Cell Therapy Market 2022 Growing with Major Eminent Key Players Anterogen Co., Ltd., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc. and Pharmicell...

InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China – Business Wire

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969) announced today that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by Chinas National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which is conditionally approved by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. Tafasitimab is not approved by the NMPA for any indication.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, We will make every effort to accelerate the clinical development of tafasitamab in combination with lenalidomide to help address the unmet needs of DLBCL patients in China.

Tafasitamab (Monjuvi) is co-commercialized by Incyte and MorphoSys in the United States and by Incyte under the brand name Minjuvi in the EU. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States, and in August 2021, Incyte entered into a collaboration and license agreement with InnoCare for the development and exclusive commercialization of tafasitamab in hematology and oncology in Greater China.

DLBCL is the most common type of non-Hodgkin lymphoma (NHL), and its incidence accounts for 31% to 34% of NHL globallyi. In China, DLBCL accounts for 45.8% of all NHLsi.

About Tafasitamab

Tafasitamab is a humanized monoclonal antibody targeting CD19.

In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).

In the United States, Monjuvi (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. This indication is approved under accelerated approval based on overall response rate. Full approval for this indication may be contingent upon results in a confirmatory trial(s).

In Europe, Minjuvi (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Tafasitamab is not approved for use in China except for in the Boao Lecheng International Medical Tourism Pilot Zone through an early access program.

Minjuvi and Monjuvi are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S. and marketed by Incyte under the brand name Minjuvi in the EU. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States, and in August 2021, Incyte entered into a collaboration and license agreement with InnoCare for the development and exclusive commercialization of tafasitamab in hematology and oncology in Greater China.

XmAb is a registered trademark of Xencor, Inc.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

i Hematology Branch of Chinese Medical Association2013

Go here to read the rest:
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China - Business Wire

OPINION: What would happen if Roe v. Wade is overturned? – Westside Eagle Observer

So, what would happen if Roe v. Wade was overturned?

Should the Supreme Court overturn the Roe v. Wade decision of 1973, the issue would go back to the states, where it was prior to the 1973 decision -- where it constitutionally belongs -- and the federal government would, as before, have no jurisdiction over the issue.

It was taken from the states in violation of Amendment 10, which reserves powers not given to the federal government in Article I, Section 8, to the states or to the people, as described in the recent column, "The Word Abortion has never been in the Constitution."

Planned Parenthood would receive no federal allocations, so their extermination centers would largely disappear.

According to the Guttmacher Institute, there are 13 states that have banned most or all abortions. These are Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, Utah and Wyoming. Five additional states have a preexisting Roe v. Wade abortion ban on the books that would probably be reactivated. These are Alabama, Arizona, Michigan, West Virginia and Wisconsin. Yet another four states currently have laws banning abortion after the six-week mark which are currently ruled unconstitutional but probably would be reversed if Roe was overturned. Finally, another four states, Florida, Indiana, Montana and Nebraska, appear likely to ban or severely restrict abortion if Roe is overturned "based upon current legislative effort" (X22 Reports, Ep. 2767B -- Much to be Revealed Renegade Panicking, The Deal Keeps Iran Quiet, Control lost. May 4, 2022).

Twenty-six states, over half of the United States, would be likely to abandon abortion as an acceptable alternative to birth control. It is increasingly difficult to make babies pay for their right to exist when they have a heartbeat at six weeks old. The stain and stench of innocent blood are in the practice and cannot be hidden anymore.

Then too, revelations of genocide by Planned Parenthood in Idaho against black babies turn the stomachs of Christian and moral people. Project Veritas caught on tape a caller's question, "What about abortions for under-aged minority groups? The Planned Parenthood employee: "Certainly, and showed a willingness to accept larger donations to abort black babies!" "Caller: We just think ... You know ... the less black kids out there the better. Planned Parenthood employee: (laughs) Understandable! Understandable!"

Abortion is the Democrat Party's sacred cow. Virtually all Democrats look the other way (a form of approval) of the genocide of their own unwanted or inconvenient humankind. If racism and eugenics have merged with the party, as appears so in the conversation above to "kill off segments of the population," such is unacceptable in any society. Reportedly 79% of Planned Parenthood clinics are in minority neighborhoods (X22 Reports, Ep. 2767B, May 4, 2022, 27:00). Planned Parenthood founder Margaret Sanger certainly supported the eugenics of black babies.

This prompted Candace Owens to say, "If it wasn't for the abortion industry, the black population would be virtually doubled today" (Tucker Carlson). Let that sink in. If blacks ever come to recognize that they have been the targeted race of white Democrats for black eugenics, the Democratic Party would cease to exist overnight and Planned Parenthood facilities would likely be burned to the ground nationwide.

Another dark secret seems to be festering in Ukraine, already seen as the Deep State laundering capital of the world for dark money, bioweapons labs, illegal drugs, etc. JuliansRum posed the question, "Where do all these aborted-baby body parts go? And follows up with Ukraine as a "baby maker" operation. He asks: "Why is Ukraine at the world's forefront of fetal stem cell therapies? -- The first fetal stem cell treatment in humans occurred at the National Medical University of Ukraine. -- The world's first center to use fetal stem cells for therapeutic purposes in humans was founded in Kyiv, Ukraine. -- The world's first-ever fully licensed fetal stem cell bank was in Ukraine. -- The world's largest fetal stem cell therapy clinic (EmCell) is in Ukraine. Stem cell anti-aging therapy is big biz there." He ends with the observation that "Ukraine has become the self-styled stem cell capital of the world" (X22 Reports, Ep. 2767B -- May 4, 2022).

BBC News was the first news outlet to focus on Ukrainian research in the area ("Ukraine Babies in Stem cell probe," BBC News, by Matthew Hill, BBC Health Correspondent, Dec. 12, 2006). The column hypothesized, "There is heated debate about the ethics of using stem cells. Healthy newborn babies may have been killed in Ukraine to feed a flourishing international trade in stem cells, evidence obtained by BBC suggests." The report "describes a general culture of trafficking of children snatched at birth and a wall of silence from hospital staff upwards."

Why Ukraine? For the same reason 13 bioweapons labs existed there. The Deep State is the Ukrainian government and is unregulated in its dark science and dark money. Ukraine appears to be the world's Deep State playground for activities that civilized nations would never permit, such as "gain of function research" on human killer diseases and/or stem cell "research on live human cells." Far-fetched? Perhaps, but that is what they said about the "nonexistent" bioweapons labs before Putin took them out -- something no longer seriously disputed. Conspiracy theories have a history of becoming conspiracy realities when enough money is attached.

So what would happen to abortion if Roe v. Wade was overturned? Almost anything from returning the issue to the states in accordance with Amendment 10 to deeper revelations about eugenics on blacks in America to even darker revelations of stem cell research to preserve the youth of rich, old people -- all positive for ending the darkest chapter in the world's history.

Frankly, I believe America is tired of the guilt and shame which always accompany the practice.

Harold W. Pease, Ph.D., is an expert on the United States Consitution and a syndicated columnist. He has dedicated his career to studying the writings of the Founding Fathers and applying that knowledge to current events. He taught history and political science from this perspective for more than 30 years. To read more of his weekly articles, visit http://www.LibertyUnderFire.org. The opinions expressed are those of the author.

Originally posted here:
OPINION: What would happen if Roe v. Wade is overturned? - Westside Eagle Observer

Hunting for the immune cells that predispose people to severe COVID-19 – EurekAlert

Some macrophages help the human body fight SARS-CoV-2 without systemic inflammation. But an aggressive subset of these immune molecules instead starts a cascade of events that can lead to multi-organ failure, researchers have discovered

image:Asst. Prof. Huanhuan Joyce Chen of Pritzker Molecular Engineering lead a new study showing that the type of macrophages present in a persons body might determine how likely they are to develop severe inflammation in response to COVID-19. view more

Credit: John Zich

When a virus makes its way into a persons body, one of the immune systems first responders is a set of pathogen-removal cells called macrophages. But macrophages are diverse; they dont all target viruses in the same way.

Researchers at the University of Chicagos Pritzker School of Molecular Engineering (PME) have discovered that the type of macrophages present in a persons body might determine how likely they are to develop severe inflammation in response to COVID-19. Their study has been published inNature Communications.

Clinicians know that COVID-19 can cause a spectrum of disease severity from mild to severe symptoms. Why some people, and not others, develop very severe disease has been a mystery, said Asst. Prof.Huanhuan Joyce Chen, who led the research with Qizhou Lian of the University of Hong Kong.This is the first time anyone has linked the variation in symptoms to macrophages.

A better model for COVID-19 infection Studying the cellular and molecular effects of the SARS-CoV-2 virus has been challenging for researchers who usually turn to model organisms to mimic human diseases; mice, rats, and many other animals dont develop the same COVID-19 symptoms as people. Thats why, shortly after the COVID-19 pandemic began, Chens group harnessed human stem cells to study the virus.

As reported previously in Nature, Chen and her colleagues grew stem cells into functioning mini-lungs and colonscalled lung and colon organoidsto probe the effects of SARS-CoV-2 on those organs and screen drugs to treat the virus.

In the new study, the researchers first analyzed lung biopsies from COVID-19 patients and discovered that they had especially high levels of macrophages. To better understand the role of macrophages during a COVID-19 infection, Chens team developed an approach that could exploit the same line of human stem cells to become both lung cells and macrophages simultaneously. The fact that they arose from the same initial stem cells was important to prevent the immune cells from attacking the lung cells.

This model system provides a perfect way to decode, step by step, how these three componentsthe immune system, the lungs, and the virusinteract, said Chen.

A cascade of inflammation When Chens lab infected the stem cell-derived lungs and macrophages with SARS-CoV-2, they found that not all macrophages responded in the same way. One subset, dubbed M2 macrophages, eliminate the virus by physically engulfing virus and virus-infected cells in a process known as phagocytosis, while releasing anti-inflammatory molecules.

M1 macrophages behaved in an opposite way: these cells released a plethora of inflammatory chemical signals that not only fight SARS-CoV-2, but cause a more widespread immune response. These same inflammatory factors have been shown to be present in the blood of people with severe COVID-19 symptoms.

Our results suggest that people who already have M1 macrophages activated in the lungs when infected with COVID-19 might be more likely to develop very severe inflammation from the virus, said Chen.

Elderly people and those with certain conditions like hypertension or diabetesalready known to be prone to more severe COVID-19 symptomsmay have higher levels of the M1 macrophages, she added.

Her team went on to show that antibodiessimilar to those already used clinically to treat COVID-19helped M2 macrophages clear the SARS-CoV-2 virus. More work is needed to show whether the observations hold true in humans, but the findings could help inform the prevention or treatment of severe COVID-19 in the most at-risk patients. And Chen is already thinking ahead to her next experiments with the stem cell-derived organoids.

This model system is useful for decoding the molecular mechanisms behind not only COVID-19, but other infectious diseases, said Chen.

In the future, her group hopes to make more complex mini-organs that include not only lung and immune cells, but blood vessels, nerves and other supporting cell types.

##

Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to read the rest:
Hunting for the immune cells that predispose people to severe COVID-19 - EurekAlert

Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare – BioSpace

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2022. Genentech and its partners will present clinical studies across medicines, comprehensive genomic tests, and real-world data at this years meeting.

At ASCO this year, progress from our portfolio, partnerships and collaborations showcase our commitment to advance innovation in cancer care, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. Were especially pleased to present data from our broad hematology portfolio, including pivotal data for glofitamab, a potential first-in-class bispecific antibody that may improve the lives of people with heavily pre-treated aggressive lymphoma.

Focusing on improving outcomes in non-Hodgkin lymphoma

New and updated data in non-Hodgkin lymphoma will be presented at ASCO. This includes pivotal data from the Phase II NP30179 study investigating glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, where as many as 40% of patients will relapse, at which point treatment options are limited and survival is shortened. Glofitamab is part of Genentechs broad bispecific antibody development program, which may offer a new immunotherapy-based approach to tackle a range of blood cancers. It is being investigated in several clinical trials including the STARGLO Phase III study, evaluating glofitamab in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera/Rituxan (rituximab) in combination with GemOx in autologous stem-cell transplant ineligible relapsed or refractory DLBCL. In addition, key findings from an analysis of the Asia subpopulation from the pivotal Phase III POLARIX study investigating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan plus cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with newly diagnosed DLBCL will be featured. Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated DLBCL in more than 20 years, potentially transforming treatment for people with this disease.

Driving innovation in personalized cancer care

More than 20 new pieces of research from partnerships with Foundation Medicine will be presented, which continue to support innovation as well as progress in personalized cancer care. This includes new data from the Phase II Profiler02 study,* which investigates the use of a comprehensive genomic profiling testing panel from Foundation Medicine, with the aim of informing possible treatment decisions for patients based on their tumors unique genomic information.

Data from the imCORE network

Additionally, three abstracts from the Immunotherapy Centers Of Research Excellence (imCORE) Network will be presented at ASCO: a Phase I study** investigating autogene cevumeran (an mRNA-based individualized neoantigen-specific immunotherapy [iNeST]***) in the adjuvant setting of pancreatic ductal adenocarcinoma; a data mining study** evaluating intermediate endpoints for survival in metastatic breast cancer in the real-world setting; and a study identifying mechanisms of acquired resistance to immune checkpoint blockade.**

imCORE is an academic-industry network for scientific collaboration. Established by Genentech and connecting experts from 26 leading institutions around the globe, imCORE is committed to advancing and accelerating cancer immunotherapy research. imCORE is an example of Genentechs dedication to collaborating with the global cancer community to further understand cancer biology and immunology, help inform the development of potential future treatment, and transform patients lives.

Genentechs data presented at ASCO will feature its efforts to drive innovation and commitment to health equity through delivery of pioneering medicines and personalized cancer care that together improve outcomes for every patient while reducing the cost to society, inclusive clinical trials that remove barriers to participation, partnerships that multiply our ability to address challenges in cancer care, and bringing innovation into earlier stages of disease to maximize a chance of cure.

Overview of key presentations featuring Genentech medicines

Medicine

Abstract title

Abstract number

Blood cancer

Glofitamab

Glofitamab in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and 2 prior therapies: Pivotal Phase II expansion results

#7500

Mosunetuzumab

CELESTIMO: a Phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received 1 line of systemic therapy

#TPS7588

Polivy

Asia subpopulation analysis from the Phase III POLARIX trial

#7558

Initial safety run-in results of the Phase III POLARGO trial: polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

#7551

Lung cancer

Tiragolumab

SKYSCRAPER-02: primary results of a Phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) plus carboplatin plus etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)

#LBA8507

Breast cancer

Giredestrant

Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2 eBC): final analysis of the randomized, open-label, international Phase 2 coopERA BC study

#589

Inavolisib

Long-term safety of inavolisib (GDC-0077) in an ongoing Phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib (palbo) and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2) metastatic breast cancer (BC)

#1052

Tumor agnostic treatment and personalized healthcare

Rozlytrek

Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST)

#LBA9023

Rozlytrek

Trial in progress: a randomized Phase 3 study of entrectinib vs crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)

#TPS9141

Comprehensive genomic profiling

(IIS, Centre Lon Brard)

Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized Phase II trial*

#3130

Comprehensive genomic profiling

Clinical and genomic characteristics of patients with durable benefit from immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC)

#9048

Comprehensive genomic profiling

ctDNA Shed as a Tool to Select Immune Checkpoint Inhibitors (ICPI) with or without Chemotherapy for Patients (pts) with advanced Non-small Cell Lung Cancer (aNSCLC)

#9045

Comprehensive genomic profiling

Trial in progress: LCMC LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers

#TPS8596

Real world data

A real world (rw) evidence study quantifying the clinical value of multi-gene testing in early-stage lung adenocarcinoma (LUAD)

#8525

Real world data

Real world analysis of quantitative MET copy number (CN) as a biomarker in advanced NSCLC (aNSCLC)

#9123

Real world data

Ancestry-based differences in gene alterations in non-small cell lung cancer: real-world data using genetic ancestry analysis

#9125

imCORE,

ISR, Genentech

Identifying mechanisms of acquired immune escape from sequential, paired biopsies**

#2519

imCORE

ISR, Dana-Farber Cancer Institute

Real-World Progression-Free Survival (rwPFS) and Time to Next Line of Therapy (TTNT) as Intermediate Endpoints for Survival in Metastatic Breast Cancer: A Real World Experience**

#6520

imCORE

ISR, Memorial Sloan Kettering Cancer Center

Phase I Trial of Adjuvant Autogene Cevumeran, an Individualized mRNA Neoantigen Vaccine, for Pancreatic Ductal Adenocarcinoma**

#2516

* IIS, investigator-initiated study

** ISR, institution-sponsored research

*** jointly developed by Genentech and BioNTech

About Polivy (polatuzumab vedotin-piiq)

Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkins lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL.

Polivy U.S. Indication

Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies.

The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy.

Important Safety Information

Possible serious side effects

Everyone reacts differently to Polivy therapy, so its important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patients doctor may stop or adjust a patients treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects.

Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patients doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns

Side effects seen most often

The most common side effects during treatment were:

Polivy may not be for everyone. A patient should talk to their doctor if they are:

These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment.

Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit http://www.Polivy.com for the full Prescribing Information for additional Important Safety Information.

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq U.S. Indications

Tecentriq is a prescription medicine used to treat adults with:

See original here:
Data at the 2022 ASCO Annual Meeting Highlight Genentech's Continued Commitment to Innovation in Oncology and Personalized Healthcare - BioSpace

How the Metaverse Will Reshape Mental Health Therapy – Entrepreneur

Opinions expressed by Entrepreneur contributors are their own.

The tech industry has seen a seismic shift in awareness around the metaverse following Facebook's rebranding to Meta and announcements about its development from other tech leaders like Microsoft, AMD, Nvidia and Epic Games. However, it's true potential lies beyond gaming, social media and consumer technology. For one thing, therapy in this new format, could soon become the standard way to get and provide mental health care.

In this digital age of interconnectedness, our society has become more cut-off than ever before. A recent report by Harvard suggests that 36% of all Americans, including 61% of young adults, feel serious loneliness, which recent research indicates is a key risk factor for mental health conditions. One study by the American Cancer Society analyzed data from more than 580,000 adults and found that social isolation increases the risk of premature death for every race.

Unable to access face-to-face care during the pandemic, many people are turning to support online. As VR headsets grow in popularity, that same technology could soon become an essential tool for therapy that is more engaging than traditional telemedicine or mobile apps.

Related:Into theMetaverse: How Digital Twins Can Change the Business Landscape

Many healthcare companies are developing innovative new business models in the metaverse to solve current challenges. Companies that make therapy sessions more human will be the ones that will make the greatest impact on therapy in the metaverse.

Most people still prefer in-person care, as evidenced by a recent survey by The Harris Poll finding that 80% of US patients always prefer face-to-face visits. This is mainly because sessions that take place in a therapist's office provide a space away from everyday life, and can increase trust when compared to digital therapy.

Conversely,a recent pollconducted byBetterHelp, found that 35% of those surveyed claimed that their opinion of how a therapy session went, wasdependent on which day of the week the appointment took place, the weather outside (31%) or by recent current events (30%).

Thats why the metaverse care model has the potential to radically change how digital therapy is delivered. Simply put, its as close to being in-person as you can get.

Being able to access support without geographical limitations from the comfort of your home has already taken off with telemedicine, but the metaverse provides a much more life-like experience.

This new increased depth of immersion can create greater engagement, focus, and connectedness compared to other digital therapy solutions. The natural environments and the intuitive nature of the design can also lead to a greater bond between patients and providers. There is a possibility that treatment outcomes can be improved due to these potential benefits but more research is needed to find out the best way to deliver therapy through VR.

My company, Rocket VR Health, is getting ready to launch a clinical trial exploring the use of mental health therapy delivered via virtual reality in patients undergoing stem cell transplantation. We have partnered with Massachusetts General Hospital in Boston to take a well-researched conventional therapy program and transform it into an immersive VR treatment.

We hypothesize that the result will be a more effective, accessible, and data-driven approach to therapy, which could be invaluable not just for the participants in the trial, but also for countless individuals suffering from mental health conditions for years to come.

Related:The 3 Biggest Challenges to Marketing in theMetaverse

Despite all the Facebook and Web3 metaverse hype, the reality is VR headsets are expensive, and though usage is growing, its estimated that only 12.5 millionwere sold in 2021. The majority of the metaverses that currently exist are for entertainment and healthcare is typically much slower to catch on.

For starters, healthcare providers must ensure that they properly manage patient data and provide security that meets the highest standards of mental healthcare.

In addition, further research needs to be done to prove the efficacy of VR therapy and convince insurance companies to cover this new treatment delivery method. Were hoping that research like our study with Massachusetts General will help make the case. Previous research findings are positive, and the FDA approved the first VR software as a medical device to treat pain management. Meanwhile, insurance companies are already covering VR-based telemedicine.

Lastly, the most compelling therapy offerings will provide headsets to patients directly, so that access to the most well-researched, cutting-edge treatments isnt dependent upon individual purchases of VR technology by consumers.

The exciting news is that a small but growing group of researchers, technologists and investors are already beginning to overcome these challenges. Slowly but surely, the metaverse will be a bigger part of all of our lives, and given the proper attention mental health may prove to be one of its best use cases in due time.

Related:Why Intellectual Property Will Dominate NFTs

Originally posted here:
How the Metaverse Will Reshape Mental Health Therapy - Entrepreneur

Premature Ovarian Failure Treatment Market Size 2022 Share, New Trends, Industry News, Business Growth, Top Key Players Analysis to 2028 The Daily…

Premature Ovarian Failure Treatment Market Report Scope and Overview

The Premature Ovarian Failure Treatment market research report includes detailed information on rising trends, market drivers, development opportunities, and market restraints that may have an impact on the industrys market dynamics. It includes product, application, and competition analyses, as well as a thorough examination of market segments. Primary research with industry professionals and opinion leaders from around the world backed up the findings. Various market estimation and data validation approaches are used to compile and validate the data. We also have an in-house data forecasting process that we utilize to forecast market growth. The study looks at important players, key collaborations, mergers and acquisitions, as well as contemporary innovation and corporate policy.

Get FREE Sample Report @ https://www.intelligencemarketreport.com/report-sample/589744

Major Market Players

Strategic analysis, micro and macro market trend and scenarios, pricing analysis, and a holistic assessment of market situations in the near future are all included in the study report. Its a thorough examination of fundamental and secondary drivers, market share, leading segments, and regional analysis. New product releases, untapped geographies, recent advances, and investments are highlighted in this Premature Ovarian Failure Treatment market research. This research contains detailed information on profitable growing markets as well as a market penetration analysis of mature categories.

Market Segmentation

Based on previous estimations, the studys goal is to project market sizes for specific categories and geographies in the coming years. The Premature Ovarian Failure Treatment market research is designed to offer both qualitative and quantitative information on the industry in each of the studys areas and countries. The research also includes a comprehensive analysis of the competitive landscape and key firms product offerings, as well as available micro market investment options for stakeholders.

Premature Ovarian Failure Treatment Market Segmentation, By Type

Premature Ovarian Failure Treatment Market Segmentation, By ApplicationByproduct

Premature Ovarian Failure Treatment Market Segmentation, By Region

Ask For Customized Report As Per Your Business Requirement @ https://www.intelligencemarketreport.com/send-an-enquiry/589744

Competitive Scenario

The research includes a SWOT analysis as well as a complete industry analysis based on Porters five forces model. It compares how different providers do in terms of revenue creation and client base. This study examines the competition landscape, capacity, and recent developments such as mergers, acquisitions, and investments of the following key competitors in the global Premature Ovarian Failure Treatment market. The report also covers some key suggestions that can help market participants to beat their competition.

Key Objectives of Market Research Report

Study of key player shares, new innovations, and tactics in the competitive scene.

Data on demand and supply forces, as well as their impact on the market, can be acquired at the regional, sub-regional, and country levels.

Information on key Premature Ovarian Failure Treatment market segments and sub-segments, including quantitative, qualitative, value, and volume data.

The report contains a wealth of information, including market dynamics and opportunities for the forecast period.

Table of Content Analysis of Key Points

Chapter 1. Executive Summary

Chapter 2. Global Market Definition and Scope

Chapter 3. Global Market Dynamics

Chapter 4. Global Market Industry Analysis

Chapter 5. Global Market, by Type

Chapter 6. Global Market, by Application

Chapter 7. Global Market, Regional Analysis

Chapter 8. Competitive Intelligence

Chapter 9. Research Process

Continued

Purchase This Report @ https://www.intelligencemarketreport.com/checkout/589744

Contact Us:Akash AnandHead of Business Development & Strategy[emailprotected]Phone: +44 20 8144 2758

Originally posted here:
Premature Ovarian Failure Treatment Market Size 2022 Share, New Trends, Industry News, Business Growth, Top Key Players Analysis to 2028 The Daily...